Can ICER Put a Price on Asthma Control?

The Institute for Clinical and Economic Review says new medicine for uncontrolled asthma isn’t worth its cost. But its analysis omits key details.

Impact Data
ICER notes that ER visits, reduction in corticosteroids, and change in FEV1 are key factors. But only some of the studies that inform ICER’s analysis include these data.

Effect on Children
ICER explains that uncontrolled severe asthma can affect children throughout their lives, but it doesn’t include the cost of this impact in its analysis.

Quality of Life
ICER’s analysis does not take into account quality of life factors like the ability to sleep, exercise and stay productive at work.

Disparities
Uncontrolled asthma can compound existing disparities for low-income or African-American patients, but ICER’s analysis does not account for these disparities.